Evaluation of polyphenols from <i>Broussonetia papyrifera</i> as coronavirus protease inhibitors

Park, Jiyoung; Yuk, Heung Joo; Ryu, Hyung Won; Lim, Su Hwan; Kim, Kyung Soo; Park, Ki Hun; Ryu, Young Bae; Lee, Woo Song

doi:10.1080/14756366.2016.1265519

Cited by 255 publications

(224 citation statements)

References 21 publications

Supporting

Mentioning

220

Contrasting

Unclassified

Order By: Relevance

“…Park et al assessed the inhibitory activity of polyphenols derived from B. papyrifera against SARS-and MERS-CoVs [103]. The isolated polyphenols markedly inhibited 3CL and PL CoV proteases of both SARS and MERS.…”

Section: Mers-cov and Sars-cov Pl Proteases Inhibitorsmentioning

confidence: 99%

Recent discovery and development of inhibitors targeting coronaviruses

Pillaiyar

Meenakshisundaram²,

Manickam

2020

Drug Discovery Today

312

315

View full text Add to dashboard Cite

Section: Mers-cov and Sars-cov Pl Proteases Inhibitorsmentioning

confidence: 99%

Recent discovery and development of inhibitors targeting coronaviruses

Pillaiyar

Meenakshisundaram²,

Manickam

2020

Drug Discovery Today

312

315

View full text Add to dashboard Cite

“…In fact, after the outbreak of SARS, many groups dedicated themselves to finding anti-coronavirus agents, including some natural compounds that exist in traditional Chinese herbal medicines [4][5][6][7][8][9][10][11][12]. The coronavirus encodes more than one dozen proteins, some of which are essential to viral entry and replication.…”

Section: Introductionmentioning

confidence: 99%

In silico screening of Chinese herbal medicines with the potential to directly inhibit 2019 novel coronavirus

Zhang¹,

Zhang³

et al. 2020

Journal of Integrative Medicine

404

379

View full text Add to dashboard Cite

a b s t r a c tObjective: In this study we execute a rational screen to identify Chinese medical herbs that are commonly used in treating viral respiratory infections and also contain compounds that might directly inhibit 2019 novel coronavirus (2019-nCoV), an ongoing novel coronavirus that causes pneumonia. Methods: There were two main steps in the screening process. In the first step we conducted a literature search for natural compounds that had been biologically confirmed as against sever acute respiratory syndrome coronavirus or Middle East respiratory syndrome coronavirus. Resulting compounds were cross-checked for listing in the Traditional Chinese Medicine Systems Pharmacology Database. Compounds meeting both requirements were subjected to absorption, distribution, metabolism and excretion (ADME) evaluation to verify that oral administration would be effective. Next, a docking analysis was used to test whether the compound had the potential for direct 2019-nCoV protein interaction. In the second step we searched Chinese herbal databases to identify plants containing the selected compounds. Plants containing 2 or more of the compounds identified in our screen were then checked against the catalogue for classic herbal usage. Finally, network pharmacology analysis was used to predict the general in vivo effects of each selected herb. Results: Of the natural compounds screened, 13 that exist in traditional Chinese medicines were also found to have potential anti-2019-nCoV activity. Further, 125 Chinese herbs were found to contain 2 or more of these 13 compounds. Of these 125 herbs, 26 are classically catalogued as treating viral respiratory infections. Network pharmacology analysis predicted that the general in vivo roles of these 26 herbal plants were related to regulating viral infection, immune/inflammation reactions and hypoxia response. Conclusion: Chinese herbal treatments classically used for treating viral respiratory infection might contain direct anti-2019-nCoV compounds.

show abstract

“…Twenty eight compounds suggested by Wu et al [15], 16 compounds suggested by Arya et al [13], 9 known inhibitors of PLPro of SARS-CoV or MERS-CoV or other related viruses were included. Also, 5 compounds suggested by Kim et al [16], 10 polyphenols suggested by Park et al [17], and hydroxychloroquine were included in the modeling analysis. All the structures were downloaded from the NCBI PubChem compounds database.…”

Section: Methodsmentioning

confidence: 99%

In search of drugs to counter the countermeasures of SARS-CoV-2 in evading host’s innate immune defense: a Molecular modeling approach.

Choudhury

Borah

Mazumder³

et al. 2020

Preprint

View full text Add to dashboard Cite

The coronaviruses (CoV), including SARS-CoV, MERS-CoV and the novel SARS-CoV-2, evade the host innate immunity employing Papain-like protease (PLPro). PLPro performs deubiquitination and deISGylation of host proteins and signaling molecules, and thus antagonize the host’s innate immune response. Thus, PLPro is a promising drug target against SARS-CoV-2. The present study employs molecular modeling approaches to determine potential of different compounds as inhibitors of the PLPro. The results demonstrated that drugs like Stallimycin, and known PLPro inhibitors including Telaprevir, Grazoprevir and Boceprevir, were highly potent in inhibiting the enzyme. In addition, several plant-derived polyphenols were also found to be potent inhibitors.

show abstract

Evaluation of polyphenols from Broussonetia papyrifera as coronavirus protease inhibitors

Cited by 255 publications

References 21 publications

Recent discovery and development of inhibitors targeting coronaviruses

Recent discovery and development of inhibitors targeting coronaviruses

In silico screening of Chinese herbal medicines with the potential to directly inhibit 2019 novel coronavirus

In search of drugs to counter the countermeasures of SARS-CoV-2 in evading host’s innate immune defense: a Molecular modeling approach.

Contact Info

Product

Resources

About